Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Ferrari

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
Haematologica|February 10, 2016
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana LinfomiStefano Sacchi, Raffaella Marcheselli, Alessia Bari, et al.
Ocular Immunology and Inflammation|August 11, 2021
Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined ChemotherapyFabrizio Gozzi, Raffaella Aldigeri, Valentina Mastrofilippo, et al.
Hematological Oncology|May 20, 2017
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana LinfomiStefano Luminari, Elda Viel, Andrés José Maria Ferreri, et al.
Chest|March 26, 2009
Performance of tests for latent tuberculosis in different groups of immunocompromised patientsLuca Richeldi, Monica Losi, Roberto D'Amico, et al.
Haematologica|January 14, 2017
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana LinfomiFrancesco Zaja, Simone Ferrero, Caterina Stelitano, et al.
American Journal of Hematology|August 12, 2020
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapiesMarzia Varettoni, Angela Ferrari, Anna M Frustaci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2017
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular LymphomaStefano Luminari, Angela Ferrari, Martina Manni, et al.
Blood|October 3, 2013
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive programMarco Ladetto, Chiara Lobetti-Bodoni, Barbara Mantoan, et al.
Blood|July 12, 2019
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 studyStefano Luminari, Michele Merli, Sara Rattotti, et al.
Blood Advances|February 12, 2026
Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström Macroglobulinaemia? A real-life multicentre Italian studyFrancesco Autore, Alessandra Tedeschi, Giulia Benevolo, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
Haematologica|February 10, 2016
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana LinfomiStefano Sacchi, Raffaella Marcheselli, Alessia Bari, et al.
Ocular Immunology and Inflammation|August 11, 2021
Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined ChemotherapyFabrizio Gozzi, Raffaella Aldigeri, Valentina Mastrofilippo, et al.
Hematological Oncology|May 20, 2017
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana LinfomiStefano Luminari, Elda Viel, Andrés José Maria Ferreri, et al.
Chest|March 26, 2009
Performance of tests for latent tuberculosis in different groups of immunocompromised patientsLuca Richeldi, Monica Losi, Roberto D'Amico, et al.
Haematologica|January 14, 2017
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana LinfomiFrancesco Zaja, Simone Ferrero, Caterina Stelitano, et al.
American Journal of Hematology|August 12, 2020
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapiesMarzia Varettoni, Angela Ferrari, Anna M Frustaci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2017
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular LymphomaStefano Luminari, Angela Ferrari, Martina Manni, et al.
Blood|October 3, 2013
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive programMarco Ladetto, Chiara Lobetti-Bodoni, Barbara Mantoan, et al.
Blood|July 12, 2019
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 studyStefano Luminari, Michele Merli, Sara Rattotti, et al.
Blood Advances|February 12, 2026
Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström Macroglobulinaemia? A real-life multicentre Italian studyFrancesco Autore, Alessandra Tedeschi, Giulia Benevolo, et al.
Pageof 12